Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13409400 | 0.81 | ELANE (0.35) | MAPTRAB9APDE5AMAPK1HSD17B10 | |
| SCHEMBL8135270 | 0.81 | PDE5A (0.36) | MAPTRAB9APDE5AMAPK1HSD17B10 | |
| SCHEMBL25393220 | 0.77 | HTT (0.40) | MAPTMAPK1ALDH1A1PDPK1NPC1 | |
| SCHEMBL2973054 | 0.71 | ADORA2A (0.41) | MAPTPDE5AHSD17B10ALDH1A1MAPK8 | |
| SCHEMBL15483504 | 0.70 | KMT2A (0.36) | MAPTRAB9AMAPK1HSD17B10ALDH1A1 | |
| SCHEMBL8277736 | 0.70 | KDM4E (0.48) | MAPTRAB9AMAPK1HSD17B10ALDH1A1 | |
| SCHEMBL8273088 | 0.68 | MAPT (0.36) | MAPTRAB9APDE5AALDH1A1PDPK1 | |
| SCHEMBL13409404 | 0.67 | MAPT (0.35) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1330351 | 0.66 | PDPK1 (0.44) | MAPTRAB9AMAPK1ALDH1A1PDPK1 | |
| SCHEMBL8274174 | 0.66 | ALDH1A1 (0.35) | MAPTRAB9AALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749961-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7749961-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7749961-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20090264346-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264346-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264346-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| EP-1730167-A4 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INT (DE) | 2008-04-09 | — | — | EP | disclosed |
| EP-1730167-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | Boehringer Ingelheim International GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| US-20050192212-A1 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-01 | — | — | US | disclosed |
| WO-2005070955-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070955-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192212-A1 | Macrocyclic peptides active against the hepatitis C virus | CTRL, RNPEP, RNASE1 | MAPT 4135/4885RAB9A 2101/4885PDE5A 3814/4885 |
| US-20090264346-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | CTRL, RNPEP, RNASE1 | MAPT 4135/4885RAB9A 2101/4885PDE5A 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.